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Abstract: Pharmacological targeting of memory cells is an attractive treatment strategy in various
autoimmune diseases, such as psoriasis and rheumatoid arthritis. Multiple sclerosis is the most
common inflammatory disorder of the central nervous system, characterized by focal immune
cell infiltration, activation of microglia and astrocytes, along with progressive damage to myelin
sheaths, axons, and neurons. The current review begins with the identification of memory cell
types in the previous literature and a recent description of the modulation of these cell types in
T, B, and resident memory cells in the presence of different clinically approved multiple sclerosis
drugs. Overall, this review paper tries to determine the potential of memory cells to act as a target for
the current or newly-developed drugs.
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1. Recent Insights into Inflammatory Neuronal Injury in Multiple Sclerosis
Multiple sclerosis is one of the most prominent demyelinating disorders, and makes a bridge
between immune and neuronal systems by degenerating the neuronal myelin sheath through a series
of inflammatory mechanisms. Scientists over the decades have attempted to investigate the exact
immune mechanisms underlying the degeneration of the myelin sheath.
The classification of multiple sclerosis is as clinically isolated syndrome (CIS), primary progressive
multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), and relapsing-remitting
multiple sclerosis (RRMS), depending on the progression and relapses of the disease [1]. The roles of
memory T or B cells are prominent in each of the different forms of the disease, but its role is more
prominent in the relapsing forms, as explained later in detail. The interesting fact is that the multiple
sclerosis drugs prescribed for various forms of multiple sclerosis have a major impact on the functionality
and abundance of T and B memory cells. Memory cells by definition are a group of cells which have
the experience of antigen recognition in a lifetime of T or B cells. They represent the distinctive
features of the adaptive immune functionality, and their mode of action and phenotypic features are
distinct depending on the cell types. Human memory T cells, B cells, and resident memory T cells are
CD45RO+CD45RA−, IgD+CD27+, and CD69+CD103+, respectively (cell surface antigens). The origins
and functions of the T and B cells are different, but both T and B cells have the same division of labor:
plasma cells secreting antibodies in the B cell part does the job of protective memory, and effector
memory T cells (TEMs) does the same function by migrating immediately to the inflamed peripheral
tissue and displaying necessary effector functions. Memory B cells perform the function of proliferation
and stimulation in response to antigenic stimulation, whereas central memory T cells (TCMs) do the same
job by homing in the secondary lymphoid organs and readily transform into TEMs while encountering
the antigens [2]. To support this function, TCMs express chemokine receptor CCR7 and the adhesion
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molecule L selectin (CD62L), allowing them to access the lymph nodes from blood, and TEMs express
low levels of these two chemokine receptors, permitting them to approach peripheral tissue such as
skin [3,4]. TCMs home to the lymph nodes and have a limited capacity to have effector functions
until they are stimulated by the secondary responses, whereas TEMs home to peripheral tissue and
rapidly produce effector cytokines upon antigenic stimulation. The effector cell type can give rise to
the long-lasting tissue-resident memory T cells (TRMs) which might protect against multiple encounters
of the similar group of pathogens, and which might help to develop vaccines or drugs in future [5].
2. Role of Memory T Cells in the Pathogenesis of Multiple Sclerosis
An earlier report from the group of Hedlund, G. et al. has shown that the sustained increase of
CD4+ memory T cells in the cerebrospinal fluid of multiple sclerosis patients compared to the peripheral
blood was a normal phenomenon [6]. A later report in the 1990s by the group of Zaffaroni, M. et al.
observed the augmented conversion from naïve to memory cells in chronic-progressive multiple
sclerosis [7]. Further, there is a definite trend of increase in memory CD45RO+CD4+ T cells and
a decrease in naïve CD45RA+ T cells in the peripheral blood of multiple sclerosis patients. Additionally,
there is a significant elevation of CD4/CD8 ratio [8]. In parallel, the role of memory cells in identifying
the myelin basic protein (MBP) or myelin antigen-specific T cells was continuously explored in several
publications. Most of the myelin-reactive T cells were shown to exist in the memory T cell subset [9].
Memory T cells are activated and proliferated even with the lack of CD28 co-stimulation [10,11].
Thus, this kind of co-stimulation blockade is not an effective strategy to prevent the MS responses.
Besides CD28, later study initiated the chance of Inducible COStimulator (ICOS)-co-stimulation as
an effective target for the autoimmune demyelinating disorder [12–14]. As mentioned, CD4+CD28−
cells have the full potential to proliferate in the central nervous system—a site which is devoid of any
professional antigen-presenting cells [15]. During this period, there was also a search to determine
if any cytokine has the potential to enhance the effector function of memory cells upon adoptive
transfer. It was indeed possible to find that the transforming growth factor-beta has the efficiency to
increase the memory phenotype of the cultured cells and effector function of the cells upon adoptive
transfer into an experimental autoimmune encephalomyelitis animal model [16]. An enhanced
expression of CD45RO+ memory T cells and decreased expression of CD45RA+ naïve T cells while
immunophenotyping the peripheral blood from the patients of another form of neurodegeneration
(Parkinson’s Disease) was also observed around this time [17]. After the establishment of the role
of memory T cells as one of the major culprits, there was a continuous trial to determine which
memory subset is important in case of the presence of disease or application of the drug. Some of
the examples from this investigation are the following: In a transcriptomic study, fingolimod increases
the effect of CCR7− TEMs in the peripheral blood of the patients [18–21]. On the other hand, another
important drug for this disease, dimethyl fumarate (methyl ester of fumaric acid), was shown to
lower the proportion of circulating TCM and TEM in compared to naïve T cells [22]. Further, there was
a decreased presence of Th1 CD4+ cells, increase in the abundance of Th2 CD8+ cells, and an unaltered
presence of Th17+ cells in the presence of this drug [23]. Interestingly, another clinically approved drug,
natalizumab (monoclonal antibody targeting adhesion molecule α4-integrin), increased the IFN-γ and
IL17A cytokines secreted by CD4+ memory T cells and reduced the CD49d+ Treg cells more than the
Th1 or Th17 cells [24]. In contrast, a later study showed unchanged memory, naïve, or effector T cells
with the affected B cell population [25]. In the presence of other two approved drugs viz interferon
beta (glycoprotein) and glatiramer acetate (immunomodulator), there was a beneficial decline of
TCMs and an increase of naïve cells [26]. In a recent paper, there was an attempt to explain the
association between MS, viral infection, and MS-drugs (fingolimod and natalizumab). They pointed
out Th1/Th17 central memory cells can be targeted to protect from both the MS-induced relapses and
virus-induced encephalomyelitis [27]. The investigation also found that memory cells have a favorable
phenotype compared to the naïve cells to breach the blood–brain barrier. The reason being was
the invadosome-like protrusions in them were 2–3 fold increased compared to the crawling naïve
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T cells that helped them to cross long distances (150 µm) on endothelial tight junctions before crossing
the blood–brain barrier [28,29]. As the functions and origins of TCM and TEM differ, the modulation of
these populations either in the lymph node or periphery in the presence of several MS drugs can also
have an aftermath effect on relapses after exposure to the drugs.
3. Role of Memory B Cells in the Pathogenesis of Multiple Sclerosis
The depletion of CD19+CD27+ B memory cells in the presence of natalizumab and the long-term
persistence of this status in the presence of other depleting factors like CD52 and CD20 strengthened
the importance of B memory cells in this autoimmune demyelinating disorder [30]. Along with this line,
the investigations supported the depletion of memory B cells in presence of other MS drugs, as observed
in case of memory T cells. Exploring different kinds of memory cells also resolves the underlying
mechanism of action of the drugs. For example, the therapeutic mode of action of dimethyl fumarate
(DMF) in treating relapsing-remitting multiple sclerosis is still not properly understood. In a recent
paper, memory B cells in circulating mature/differentiated B cell type was significantly diminished while
treating with this drug. The DMF-mediated decrease leads to the reduction of the pro-inflammatory
signals (GM-CSF, IL-6, TNF-α) compounded with reduced phosphorylation of STAT5/6 and NF-κB in
surviving B cells [31]. An earlier report mentioned that this drug increased the amount of B cells with
regulatory capacity (IL-10 producing B cells) [32]. Fingolimod used for treating relapsing-remitting
multiple sclerosis was shown to have broad effects on the increase/decrease of the cell populations
similar to DMF. It increases the naïve to memory cell phenotype, modulates the circulatory B cells with
an abundance of regulatory capacity and an increase of anti-inflammatory cytokines [33]. Another
first-line disease-modifying drug, interferon-beta (IFN-β), has both anti-inflammatory properties and
can effectively target the memory B cells [34]. To determine whether a single dose of the drug is
sufficient to eradicate the disease-causing cell subsets, it is elucidated that a single dose of rituximab
did not eliminate the IgG memory B cells and might facilitate the presence of auto-reactive immune
cells [35]. Along with memory B cells, the exploration of CD40 co-stimulation helped in identifying
the mechanistic pathway of the currently existing drugs. To support that, CD40-mediated elevation
in pP65 (NF-κB) level was observed in the naïve and memory cells from the relapsing-remitting and
progressive multiple sclerosis patients compared to the control subjects [36]. Further, the combination
therapy of IFN-β-1a (Avonex) and mycophenolate mofetil (Cellcept) and glatiramer acetate leads to
the modulation of hyperphosphorylation of P65 in B cells [36]. There was an intention to search for
the signaling molecule responsible for the propagation of granulocyte macrophage colony-stimulating
factor (GM-CSF) memory B cells, and it was found that the signal transducer and activator of
transcription 5/6 (STAT5/6)-regulated mechanistic pathway is upregulated in untreated MS patients,
and this also reciprocally regulates the IL-10 secretion [37]. It is also interesting to observe how different
external factors (e.g., Epstein-Barr virus, EBV) modulate the self- and poly-reactivity of memory B cells.
In the case of EBV infection, memory cells have evolved to have less self-reactivity which gives the virus
an opportunity to propagate more in B-memory cell type in contrast to others [38].
Table 1 explains a brief overview of the relationship between clinically-approved MS drugs and
modulation of memory cell types.
Table 1. The effect of multiple sclerosis (MS) drugs on different kinds of memory cells.
MS Drugs Memory T Cells Memory B Cells
Fingolimod Increase TCMs [39] Decreased [40]
Dimethyl fumarate Decrease of TEM and TCMs [41] Decreased [32]
Natalizumab Unchanged [25] Increased [25]
Interferon-β Decrease of TCMs [26] Decreased [34]
Glatiramer acetate Decrease of TCMs [26] Decreased [42]
Teriflunomide Not known Decreased [43]
Dalfampridine Not known Not known
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4. Role of Resident Memory Cells in Mediating Demyelinating Disorders
TRMs are the new bunch of memory cells having different transcriptional programs than effector
and central memory T cells. They are mostly present in the barrier tissues like the skin and gut. Among
the two populations of memory T cells (recirculating and resident) present in the peripheral tissue,
residency of the cells in the case of both CD4+ and CD8+ are determined by CD103 expression [44,45].
Other than CD103, the prominent activation marker used to identify the TRMs is CD69 [44,46]. In certain
tissues (e.g., skin and intestinal epithelium), there is no requirement of antigen presentation for
the CD103+CD8+ TRMs formation as a consequence of TGF-β signaling [46,47]. Along with the barrier
tissues, there are recent reports of the presence of TRMs in other non-barrier tissues like kidney and joint
inflammation. TRMs protect the barrier tissue against environmental pathogens, but a recent report
observed that TRM is generated in response to a topically-applied allergen. In a recent publication,
TCM was shown to match TRM in terms of their functions, viz being stimulated by the secondary
responses [48]. The TRMs were shown to present in the brain, evading the blood–brain barrier [49].
In this kind of CD103+CD8+ expression, the local antigen stimulation for CD103+ is necessary.
TRMs were present in the brain tissue after the in vitro infection with vesicular stomatitis virus,
and the effector population here was CD8+CD103+ type, but the factor required for the continuous
stimulation of T cells is still unclear. At the transcriptional level, brain TRM resembles well with
the skin, gut, and lungs but they are transcriptionally distinct from central and effector memory
population [49,50]. There is still a lack of evidence as to whether these kinds of memory cells are
indeed present in the brain. There is a recent report that supports the presence of CD8+ TRMs in
MS patients. In this report, relapsing-remitting and chronic forms of the disease were mediated by
the tissue-resident CD8+ lymphocytes, and the acute form of the disease was regulated by the effector
memory population residing in the meninges and perivascular space [51].
5. Novel Therapies Targeting Memory Cells with a Future in Clinical Development
The most important knowledge that the modulation of memory cells brings to us is the
modification of the MS patients’ immune profiles while taking the clinically-approved drugs.
The immune-modulating mechanism in the case of both T or B cells is the elevation of naïve immune
cells compared to the memory cells and the shift towards the anti-inflammatory paradigm, both of
which ensure the elimination of auto-aggressive immune cells. With the increasing knowledge, the final
goal will be to use different immunomodulators which may prevent the relapsing of MS. One such
example of the new class of modulator is VitD3, the application of which in vitro in the peripheral blood
mononuclear cells can abrogate the proportion of effector memory T cells and enhance the abundance
of naïve cells [52]. Further investigations in this direction may yield innovative treatment either with
the existing approved drugs, or in combination with other new classes of immunomodulators.
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